Announcements Trials
Browse Landscape

Phase

Phase NA 14Phase EARLY_PHASE1 1Phase 4 1Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 182Neoplasms 115Prostatic Neoplasms 103Multiple Myeloma 86Glioblastoma 82Pancreatic Neoplasms 76Glioma 66Brain Neoplasms 60Lung Neoplasms 58Head and Neck Neoplasms 57Melanoma 55Colorectal Neoplasms 55Carcinoma, Non-Small-Cell Lung 53Leukemia, Myeloid, Acute 51Carcinoma, Hepatocellular 51Recurrence 47Squamous Cell Carcinoma of Head and Neck 46Ovarian Neoplasms 45Lymphoma 40Lymphoma, Non-Hodgkin 37Sarcoma 36Lymphoma, B-Cell 36Stomach Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 34Solid Tumor 31Hematologic Neoplasms 31Carcinoma, Renal Cell 30Polycystic Ovary Syndrome 27Burkitt Lymphoma 27

Interventions

gadoterate meglumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Interventional × Fibroadenoma × Clear all
NCT04341129 2023-12-05

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

University of Chicago

Phase EARLY_PHASE1 Completed
50 enrolled
Breast

Breast Diseases, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Fibroadenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡